Children Exposed to HIV, HIV, HIV-uninfected Children
Conditions
Keywords
early ART, neurocognitive evaluation
Brief summary
This study aims to perform a comprehensive neuro-cognitive evaluation of the 4-7 year old children from the Pediacam cohort (ANRS 12140 /12225, NCT02043418). It is expected thereby to provide complementary information to the trials CHER and PREDICT on the long term development of (1) HIV-infected children according to age at ARV initiation and (2) HIV exposed but not infected children, all compared with the control group of children uninfected, unexposed to HIV.
Detailed description
Cognitive, motor and sensorial impairments associated to HIV infection have been and remain important concerns in children. The advent of ARV has reduced the frequency and the extent of HIV-related encephalopathys, but literature suggests that more limited impairments remain (CHER and PREDICT trials). These neuro-cognitive disorders might constitute an important public health problem in sub-Saharan Africa where a high percentage of children born to HIV+ women live. Nevertheless,the knowledge on their long-term consequences on children development in this context remains limited. Data on the burden of cognitive, motor and sensorial impairment in resource-limited settings as well as on the interaction with other factors that could also impair children development are scarse. The Pediacam cohort gives the opportunity to better understand the development of children born to HIV-infected mothers - infected by HIV or not - followed up from birth and living in sub-Saharan Africa.
Interventions
OTHERHIV-infected children initiated antiretroviral treatment within the first 7 months of life
All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.
Sponsors
Centre Pasteur du Cameroun
Hopital Universitaire Robert-Debre
Institut de Recherche pour le Developpement
Centre Mère et Enfant de la Fondation Chantal Biya
Hospital General De Douala
Centre Hospitalier D'essos
Inserm U1018, Equipe 4 VIH & IST
ANRS, Emerging Infectious Diseases
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to 7 Years
Healthy volunteers
No
Inclusion criteria
* Children included in the Pediacam cohort and age 4 to 7 * Parent or guardian written informed consent obtained
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments | 4-7 years of age | Frequency of cognitive, motor and sensorial impairments in 4-7 year old children born to HIV+ mothers who received early treatment in the first 7 months of life |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compared frequency of motor, cognitive and sensorial impairments between infected and uninfected children | 4-7 years of age | long term effect of HIV and/or PMTCT exposure on children exposed but not infected with HIV. Results of cognitive, motor and sensorial (hearing and visual) evaluations will be compared among cohorts. |
| Effect of early ARV (<3 months) versus differed ARV (between 3 and 7 months) on neurocognitive impairments | 4-7 years of age | long term effect of early ARV (\<3 months) versus differed ARV (between 3 and 7 months) on cognitive, motor and sensorial impairments in HIV+ children |
| Prognostic factors and consequences of HIV-associated neuro-cognitive impairments | 4-7 years of age | prognostic factors and describe consequences of HIV-associated neuro-cognitive impairments on children social life |
Countries
Cameroon
Contacts
Primary ContactMathurin Cyrille TEJIOKEM, MD, PhD
Outcome results
None listed